Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIV.
Charlotte-Paige RolleVu NguyenFederico HinestrosaEdwin DeJesusPublished in: AIDS research and therapy (2021)
In this real-world cohort, the majority of whom had virus with the M184V/I and ≥ 1 additional NA mutation, switching to DTG functional mono-or dual therapy with a non-cytosine NA resulted in persistent HIV-1 RNA ≥ 50 copies/mL in 18%. None with post-switch genotypes developed treatment-emergent resistance.
Keyphrases
- antiretroviral therapy
- end stage renal disease
- hiv infected
- ejection fraction
- chronic kidney disease
- newly diagnosed
- hiv positive
- hepatitis c virus
- human immunodeficiency virus
- type diabetes
- stem cells
- metabolic syndrome
- prognostic factors
- combination therapy
- hiv testing
- mesenchymal stem cells
- south africa
- weight loss
- patient reported outcomes